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In 2011,  over  10.1  million  people  were  held  in  prisons  around  the  world.  HIV  prevalence  is elevated  in
prison  and  this  is  due  to the  over  representation  of  people  who  inject  drugs  (PWID).  Yet  HIV  preven-
tion  programs  for PWID  are scarce  in  the  prison  setting.  With  a  high  proportion  of drug  users  and  few
prevention  programs,  HIV  transmission  occurs  and  sometimes  at an alarming  rate.
This  commentary  focuses  primarily  on  drug  users  in  prison;  their  risk  behaviours  and  levels  of  infection.
It  also comments  on  the  transmission  of  HIV including  outbreaks  and the  efforts  to  prevent  transmissionrevalence
eople who  inject drugs
ransmission
utbreaks
revention
within  the  prison  setting.
The  spread  of  HIV  in prison  has  substantial  public  health  implications  as  virtually  all  prisoners  return
to  the community.  HIV  prevention  and treatment  strategies  known  to be  effective  in  community  settings,
such  as  methadone  maintenance  treatment,  needle  and  syringe  programs,  condoms  and antiretroviral
therapy  should  be  provided  to prisoners  as  a matter  of  urgency.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-NDntroduction
Globally, in 2011 over 10 million people were held in prison
Walmsley, 2013) and of these 2.5–3 million were held in pre-trial
etention (Walmsley, 2014). However, the turnover in prison popu-
ations is estimated to be at least three times that with some 30
illion individuals being detained and released into the commu-
ity each year. Female prisoners receive even less attention than
heir male counterparts. Women  are a minority within the popu-
ation of prisoners. Typically, they make up about 5–10% of prison
opulations in most countries (Walmsley, 2013). Yet the prevalence
f drug use among them is much higher than their male coun-
erparts and drug treatment options are usually more limited for
emale prisoners than for males.
eople who inject drugs within prison populationsDrug users are vastly over represented in prison populations.
nternationally, 10–48% of male and 30–60% of female inmates
∗ Corresponding author.
E-mail address: K.dolan@unsw.edu.au (K. Dolan).
ttp://dx.doi.org/10.1016/j.drugpo.2014.10.012
955-3959/© 2015 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
have used illicit drugs in the month before entering prison (Fazel,
Bains, & Doll, 2006). In the US, between 24% and 36% of all heroin
addicts pass through the corrections system each year, representing
more than 200,000 individuals (Boutwell, Nijhawan, Zaller, & Rich,
2007). Over 60% of PWIDs in a 12-city study reported a history of
imprisonment (Ball et al., 1994) and in one Australian study, PWID
reported an average of ﬁve imprisonments (Dolan, Wodak, & Hall,
1999).
The frequent and repetitive imprisonment of drug users is the
key reason for continuous growth in the size of prison populations.
From 1996 to 2006, the US population rose by 13% and the incarcer-
ated population rose by 33% yet the proportion of prisoners with
a drug problem rose by 43%. Furthermore, the prison population
has increased in all ﬁve continents. Over the last 15 years the world
imprisonment rate has risen from 136 per 100,000 to the current
rate of 146 per 100,000 (Walmsley, 2014).
Rates of re-incarceration are especially high for inmates with a
drug problem. Drug dependent offenders are much more likely to
return to prison than other offenders. In the US, over 50% of drug
dependent inmates have a previous incarceration compared with
31% of other inmates. In Australia, 84% of heroin dependent inmates
were re-incarcerated within two  years of release compared to 44%
of all prisoners (Steering Committee for the Review of Government
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ervice Provision, 2010). These high rates show that drug offenders
re not being treated for their drug dependence while in prison.
isk behaviours in prison
Many drug users stop using and injecting drugs when impris-
ned. For other prisoners though, some will commence drug use or
witch the route of drug administration if their preferred drug is
navailable (Fazel et al., 2006). A study in Belgium found that 30%
f drug-using prisoners began using an additional drug and heroin
as the drug most frequently mentioned (EMCDDA, 2012). Accord-
ng to research across 15 European countries, between 2 and 56%
f prisoners report drug use while incarcerated and among nine
ountries the prevalence ranged from 20 to 40% (EMCDDA, 2012).
A history of injecting drug use is substantially higher among
risoners than among the general population. Reports from Europe
uggest that between 2 and 38% of prisoners have injected drugs
t some time. This is in sharp contrast to the proportion of the
ommunity who inject drugs (0.3%; EMCDDA, 2012). These ﬁgures
ighlight the need for good coverage of a range of HIV prevention
rograms for prison inmates.
Studies of prisoners ﬁnd a high level of injecting and an
xtremely high level of syringe sharing in prison. Two studies of
eneral prisoners in Greece (Koulierakis et al., 2000; Malliori et al.,
998) found 24% and 20% injected in prison and 92% and 83% shared
yringes, respectively. In a large Russian study, 10% of 1000 inmates
njected with 66% sharing syringes (Frost & Tchertkov, 2002). In
hailand, Thaisri reported that 25% of 689 inmates injected of
hom 78% shared syringes (Thaisri et al., 2003).
Studies of prisoners with a history of injecting ﬁnd even higher
ates of injecting in prison. Two Scottish surveys reported that 37%
nd 58% of injectors had injected in prison in the previous month
Bird et al., 1997). HIV positive inmates in the UK were signiﬁcantly
ore likely to inject (46% vs. 18%) and share syringes (42% vs. 12%)
han those who were HIV negative or unsure of their status (Dolan
t al., 1990). Among Australian PWID, some 30–74% reported inject-
ng in prison and 70–90% of those reported syringe sharing (Rutter
t al., 1996).
Reports from developing countries also indicate high levels of
njecting and sharing of equipment. In Pakistan, 80% of PWID had
een to jail where reports of injecting ranged from 22% to 70% and
yringe sharing was 56% (Nai Zindagi, 2009). Nepal has reported
hat 19% of inmates in ﬁve prisons had a history of injecting drugs
Dolan & Larney, 2009).
Needles and syringes are scarce in the prison setting. With
ew needles and syringes circulating among many drug injecting
nmates, sharing is inevitable. Up to 15 or 20 individuals may  inject
ith the same equipment. A study of 69 syringes conﬁscated from
rison revealed most were cut to just a few centimetres in length,
ome contained visible traces of blood and the hepatitis C virus was
etected (Dolan, Larney, Jacka, & Rawlinson, 2009). Some inmates
ake their own syringes with needle substitutes fashioned out of
ardened plastic and ball-point pens, often causing damage to veins
nd scarring (EMCDDA, 2012). All of these improvisations hamper
ny efforts to decontaminate the equipment.
IV prevalence
Given the preponderance of PWID in prison, it is unsurprising
hat the levels of HIV infection are elevated. However some ﬁgures
re extraordinarily high. For example, 28% of general prisoners in
ietnam were HIV positive in 2000 (Anonymous, 2000). In Estonia,
p to 90% of inmates were HIV positive in 2004 (Tsereteli, 2004).
Other countries have managed to control HIV infection among
heir prison populations. In Australia, HIV prevalence is almost zero,f Drug Policy 26 (2015) S12–S15 S13
even though PWID account for approximately 50% of prison popu-
lations (Butler, 2011).
HIV transmission in prison
HIV transmission in prison is difﬁcult to document owing to
uncertainties regarding precise date of infection, the rapid turnover
of inmates, low levels of HIV testing and inmates’ reluctance to
report risk behaviours to prison authorities (Dolan, 1997). Nev-
ertheless, reports of transmission have been made (Brewer et al.,
1988; CDC, 1986; Horsburgh, Jarvis, & McArthur, 1990; Mutter &
Grimes, 1994).
The ﬁrst epidemic outbreak of HIV in Thailand started among
PWID in a Bangkok prison in 1988. HIV infection among PWID in the
community rose from 2 to 43% from 1987 to 1988. The increase was
detected after hundreds of prisoners were released in an amnesty
on the King’s birthday. Further investigation found two risk factors
were independently associated with HIV infection: having shared
needles with two  or more individuals in the previous six months
and having been in prison. PWID with a history of imprisonment
were twice as likely to be HIV positive as those who had never been
imprisoned. HIV incidence in Thai prisons was  very high at 35 per
100 person years (Choopanya et al., 1991, 2002).
Lithuania and Russia both suffered major outbreaks of HIV
in particular prisons. In Lithuania, the outbreak in Alytus prison
resulted in at least 284 inmates being infected within a six month
period. These new infections doubled the total number of HIV cases
in the country (Caplinskiene, Caplinskas, & Griskevicius, 2003;
Dolan et al., 2007). Meanwhile the outbreak in a Russian prison
in Nizhnekamsk resulted in over 400 inmates in a population of
1824 acquiring HIV, again in a brief period (Nikolayev, 2014).
Although the numbers infected have not been reported, both
Ukraine and Iran experienced HIV outbreaks among their inmate
populations. In Ukraine, an HIV outbreak was registered in a min-
imum security prison colony and attributed to unprotected sexual
activity and drug injection in prison (Gunchenko & Kozhan, 1999).
Iran reported two large outbreaks of HIV in prisons with hundreds
infected (Farnia, Ebrahimi, Shams, & Zamani, 2010). These out-
breaks in Iranian prisons were the impetus for the development
of policies to allow for the introduction of needle and syringe and
methadone programs into prison.
HIV outbreaks have also occurred in prison populations even
where HIV prevalence was very low. Both Scotland (Taylor,
Goldberg, & Emslie, 1995) and Australia (Dolan and Wodak, 1999)
experienced outbreaks where between 4 and 12 inmates were
infected within a few months.
Prevention
Internationally, HIV prevention efforts in prisons have been poor
in comparison to those in the surrounding communities (Dolan
et al., 2014). HIV education is the most widely used HIV preven-
tion intervention in prisons, but is insufﬁcient unless prevention
programs are also provided. In 2012, methadone treatment was
available in prison in 41 countries even though it was available in
the community in 77 countries (HRI, 2012). Needle and syringe pro-
grams were available in prison in just 13 countries but operated
in the community in 86 countries (HRI, 2012). Meanwhile con-
doms were provided to prisoners in 28 countries but available in
the community settings in virtually all countries. This inequality of
health care provision between the community and the prison set-
ting contravenes international law as well as in international rules,
guidelines, declarations and covenants (UNODC et al., 2013).
Each and every type of these programs; methadone mainte-
nance treatment, needle and syringe programs and condoms, has
been evaluated favourably in the prison setting (Jurgens, Ball, &
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are detained and released into the community each year.14 K. Dolan et al. / International Jou
erster, 2009) but the implementation of these programs has not
mproved.
onclusion
Despite the size of the world prison population, prisoners have
een largely forgotten in the HIV response (Dolan et al., 2014).
ome of the reasons for the lack of research and action in this area
re the obstructive nature of prison authorities, the lack of inter-
st in the area by funders and the overcautious approach of ethics
ommittees. Prison authorities have been known to delay approval,
imit the scope of research questions and veto publication of results
Thomson, Reid, & Dolan, 2009). Although two thirds of the 2.3
illion inmates in the U.S. meet the DSM-IV medical criteria for
ddiction only 11% received treatment with less than 1% of prison
udgets spent on treatment (CASA, 2010).
Tens of million people are imprisoned every year and an esti-
ated 30 million pass through a correction centre each year. This
opulation is at least twice the size of the estimated population of
WID (HRI, 2012).
PWID is the main group in prison in terms of HIV risk behaviour.
ven though they make up about one third to one half of prison
opulations, they are usually detained without access to treat-
ent for drug dependence or HIV infection. Many continue to
nject while detained and some commence injecting when impris-
ned. Without interventions, their levels of syringe sharing remain
xtraordinarily high, as is their re-incarceration rate. Reports from
any countries in the developed and developing world show a
imilar pattern in terms of the overrepresentation of PWID, their
ngagement in risk behaviour, high levels of HIV infection and
ransmission.
Occasionally outbreaks of HIV among prison populations have
een the impetus for the development of policies to allow for the
ntroduction of needle and syringe and methadone programs. How-
ver, the level of implementation of HIV prevention programs is
oeful across the world; less than 50 countries provide MMT,  NSP
r condoms to prisoners. This is despite there being ample evidence
hat these programs are effective in the prison setting.
Therefore a new approach is needed to reorientate the focus
f prison policy to increase the implementation of these pro-
rams in order to protect inmates’ health. International leadership
ould come from funders such as the World Bank or the Gates
oundation.
ecommendations
There is sufﬁcient evidence to address the most frequent mode
f HIV transmission among inmates: injecting drug use. Sizeable
umbers of prisoners inject drugs while incarcerated and usu-
lly with shared injecting equipment. Therefore, the primary goal
as to be the reduction of drug injecting in prison. One way  to
chieve this is to reduce the number of drug injectors who  are
ent to prison. There is abundant evidence that community-based
ethadone treatment reduces injecting, crime and the subsequent
ncarceration of drug users.
Another way is to target pre-trial detainees; these account for
ver a third of all individuals in prisons worldwide. Prisoners are
requently held in overcrowded, substandard conditions without
edical treatment or any measures for infection control. Inter-
ational standards clearly state that pre-trial detention should be
n exceptional measure used sparingly. Therefore, programmes
roviding safe alternatives to pre-trial detention for persons
ccused of low-level crimes should be implemented (Csete, 2010).
A third way to reduce the level of drug injecting in prison is to
rovide methadone maintenance treatment during incarceration.f Drug Policy 26 (2015) S12–S15
MMT  reduces injecting and sharing in prison populations (Dolan,
Shearer, White, Zhou, & Wodak, 2005; Larney, Toson, Burns, &
Dolan, 2012). Releasing inmates on methadone treatment reduces
their chance of being re-incarcerated, and this was demonstrated
as early as 1969, in one of the ﬁrst studies of MMT  (Dole et al., 1969).
Yet prison authorities struggle with accommodating more prison
entrants, rather than provide evidence based drug treatment.
Another advantage of releasing inmates on methadone treatment
is their risk of experiencing a fatal overdose in the period imme-
diately after release (Farrell & Marsden, 2008) is greatly reduced
(Dolan et al., 2005).
Drug injecting in prison is also likely to be reduced if prisoners
receive lesser punishment for the use of non-injectable drugs com-
pared with injectable drugs. Yet prisoners usually receive the same
penalty whether they test positive on urinalysis for cannabis or for
heroin. Research in the UK found that inmates moved from smok-
ing cannabis (detectable in urine for weeks) to injecting heroin
(detectable in urine for only a day or two) after mandatory drug
testing was introduced (Boys et al., 2002). Differential sanctions for
drug use within prison should be explored as a way to reduce the
level of injecting.
The overreliance on the use of supply reduction measures within
prisons warrant investigation. Many prison authorities conduct uri-
nalysis at the expense of effective demand and harm reduction
strategies. An examination of supply reduction measures in Aus-
tralian prisons found despite an extensive use of drug searches
and urinalysis, the detection of drugs was modest. The most com-
monly used drug was cannabis with the detection of drugs such as
amphetamines and heroin being very low (Dolan & Rodas, 2014).
Without doubt, the most controversial strategy has been prison
based needle and syringe exchange programs. These programs
have been implemented in 70 different prisons in over one dozen
countries. In countries where needle and syringe programs are
provided outside prison, consideration should also be given to
providing it inside prison. The introduction of needle exchange
programmes should be carefully prepared, including providing
information and training for prison staff (UNODC, 2014).
Prisoners should have access to medical treatment and preven-
tive measures without discrimination on the grounds of their legal
situation. Health in prison is a right guaranteed in international
law, as well as in international rules, guidelines, declarations and
covenants (UNODC et al., 2013). The right to health includes the
right to medical treatment and to preventive measures as well as
to standards of health care at least equivalent to those available in
the community (Jürgens & Betteridge, 2005).
Numerous polices, handbook and manuals have been developed
to assist prison authorities to address HIV in prison. The Compre-
hensive package on HIV prevention, treatment and care in prisons
and other closed settings provides a good overview of which inter-
ventions to implement (UNODC et al., 2013).
The contents and conclusions of the paper reﬂect a broad con-
sensus among social and clinical scientists participating in a UNODC
Scientiﬁc Consultation on HIV/AIDS (UNODC, Scientiﬁc Statement,
March 11, 2014).
Conclusion statements
- The world prison population is growing. Of the 10 million pris-- Drug users make  up one and two thirds of inmates. In the
US, 200,000 heroin addicts are jailed each year. Rates of
re-incarceration are especially high for inmates with a drug
problem, yet very few receive drug treatment.
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- Some inmates stop drug use in prison. Others continue or
initiate drug use inside and among the PWID, almost all share
syringes and with a multitude of partners.
- HIV prevalence is elevated among prisoners and transmis-
sion in prison occurs sometimes at epidemic rates. HIV
prevention efforts in prisons are rarely implemented and
almost never to scale.
- Minor drug offenders need treatment not incarceration.
Imprisoned drug offenders need treatment to reduce their
risk of relapse and re-incarceration.
- Advocacy is required to reorientate the focus of prison
policies to implement drug treatment and harm reduction
programs in order to protect the health of inmates and the
general public.
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